Results 61 to 70 of about 609,040 (315)

Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan. Methods Patients who initiated daprodustat between September 2020 and July 2022 were registered.
Tadao Akizawa, Kyomi Kanaya, Kiyomi Aizawa, Masanori Onoki, Hirofumi Ozeki, Kazuko Suzuki, Ai Hayashi, Tomohiko Asamura   +7 more
wiley   +1 more source

P1222: PACIFIC: BRENTUXIMAB VEDOTIN AND NIVOLUMAB ALONE AND THEN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR UNTREATED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA PATIENTS

HemaSphere, 2022
R. Steiner, P. Strati, C. Flowers, S. Neelapu, M. Green, L. Nastoupil, F. Hagemeister, L. Feng, S. Ahmed, R. Nair, L. Fayad, H. Lee, M. A. Rodriguez, J. Westin   +13 more
doaj   +1 more source

Spatiotemporal and quantitative analyses of phosphoinositides – fluorescent probe—and mass spectrometry‐based approaches

FEBS Letters, EarlyView.
Fluorescent probes allow dynamic visualization of phosphoinositides in living cells (left), whereas mass spectrometry provides high‐sensitivity, isomer‐resolved quantitation (right). Their synergistic use captures complementary aspects of lipid signaling. This review illustrates how these approaches reveal the spatiotemporal regulation and quantitative
Hiroaki Kajiho, Shin Morioka, Junko Sasaki, Takehiko Sasaki   +3 more
wiley   +1 more source

Molecular diagnosis of Burkitt's lymphoma [PDF]

, 2006
Background: The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma is crucial because these two types of lymphoma require different treatments.
Lam, LT, Delabie, J, Braziel, RM, Ott, G, Staudt, LM, Dave, BJ, Armitage, JO, Kvaloy, S, Powell, J, Montserrat, E, Wright, GW, Smeland, EB, Jaffe, ES, Fu, K, Fisher, RI, Bahl, M, Wilson, WH, Boerma, EJ, Miller, TP, Rimsza, LM, Zhao, H, Campo, E, Dave, SS, Yang, LM, Muller-Hermelink, H, Chan, WC, Greiner, TC, Bast, M, Simon, R, Rosenwald, A, Weisenburger, DD, Kluin, P, Grogan, TM, Sanger, W, Connors, JM, Holte, H, Vose, JM, Gascoyne, RD   +37 more
core   +1 more source

PB2100: MANAGEMENT OF RELAPSED / REFRACTORY (R/R) B-CELL NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20XCD3 BISPECIFIC ANTIBODY GLOFITAMAB. A SINGLE CENTER EXPERIENCE.

HemaSphere, 2022
C. Giatra, E. Souravla, I. Darmani, A. Roumelioti, K. Kaouranis, P. Kosmas, V. Bampali, D. Gardeli, M. Papageorgiou, Z. Mellios, F. Karaolidou, I. Tsonis, M. Karatza, K. George, L. Marinos, D. Karakasis, T. Karmiris, M. Bakiri, M. Bouzani   +18 more
doaj   +1 more source

Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical study

Frontiers in Immunology
Autologous stem cell transplantation (ASCT) and chimeric antigen receptor T-cells (CAR-T) have been used as consolidation therapies for patients with refractory/relapsed B cell non-Hodgkin’s lymphoma (R/R B-NHL) in remission after second-line ...
Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Yuelu Guo, Miaomiao Cao, Yang Lei, Yimeng Dou, Xuenan Zhang, Yan Gao, Bian Wei, Biping Deng, Xiaoyan Ke, Xiaoyan Ke, Kai Hu   +15 more
doaj   +1 more source

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study [PDF]

, 2008
Summary Myelosuppression, particularly febrile neutropenia (FN), are serious dose-limiting toxicities that occur frequently during the first cycle of chemotherapy.
Impact of Neutropenia in Chemotherapy-European Study Group (INC-, Paridaens, R, Szucs, Thomas D., Matthias Schwenkglenks, Pettengell, R, Bosly, André, Schwenkglenks, Matthias, Jackisch, C, Jackisch, Christian, Thomas D. Szucs, Manuel Constenla, Constenla, Manuel, Szucs, T D, Schwenkglenks, M, André Bosly, Leonard, Robert, Paridaens, Robert, Christian Jackisch, Robert Leonard, Pettengell, Ruth, Ruth Pettengell, Robert Paridaens, Bosly, A, Impact of Neutropenia in Chemotherapy-European Study Group,, Szucs, TD, Leonard, R, Constenla, M   +26 more
core   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Anaplastic large-cell lymphoma. [PDF]

, 2011
The concept of anaplastic large-cell lymphoma (ALCL) has changed over the years because of a stream of new information and novel understanding regarding the cell of origin, biology, genetics, and clinical features of these neoplasms. This new information
European T. Cell Lymphoma Study Group, Pileri SA, FACCHETTI, Fabio, Inghirami G   +3 more
core